Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Natalizumab therapy for multiple sclerosis.

Derfuss T, Kuhle J, Lindberg R, Kappos L.

Semin Neurol. 2013 Feb;33(1):26-36. doi: 10.1055/s-0033-1343793. Epub 2013 May 25. Review.

PMID:
23709210
2.

Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.

Baldwin KJ, Hogg JP.

Curr Opin Neurol. 2013 Jun;26(3):318-23. doi: 10.1097/WCO.0b013e328360279f. Review.

PMID:
23493158
3.

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.

Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.

JAMA Neurol. 2013 Mar 1;70(3):398-402. doi: 10.1001/jamaneurol.2013.1960. Review.

PMID:
23338729
4.

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.

Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.

Mult Scler. 2012 Feb;18(2):143-52. doi: 10.1177/1352458511435105. Review.

PMID:
22312009
5.

Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.

Bartt RE.

Curr Opin Neurol. 2006 Aug;19(4):341-9. Review.

PMID:
16914971
7.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.

N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829.

8.

Treating multiple sclerosis with natalizumab.

Iaffaldano P, Lucchese G, Trojano M.

Expert Rev Neurother. 2011 Dec;11(12):1683-92. doi: 10.1586/ern.11.154. Review.

PMID:
22091593
9.

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A.

Lancet Neurol. 2010 Apr;9(4):438-46. doi: 10.1016/S1474-4422(10)70028-4. Review. Erratum in: Lancet Neurol. 2010 May;9(5):463. DeLuca, Andrea [corrected to De Luca, Andrea].

PMID:
20298967
10.

Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.

Hunt D, Giovannoni G.

Pract Neurol. 2012 Feb;12(1):25-35. doi: 10.1136/practneurol-2011-000092. Review.

PMID:
22258169
11.

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.

Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Tervaert JW, Nash RA, Hartung HP, Kieseier BC, Racke MM, Frohman EM, Hemmer B.

Arch Neurol. 2007 Feb;64(2):169-76. Review.

PMID:
17296831
12.

Natalizumab for relapsing-remitting multiple sclerosis.

Horga A, Tintoré M.

Neurologia. 2011 Jul-Aug;26(6):357-68. doi: 10.1016/j.nrl.2010.10.004. Epub 2010 Dec 28. Review. English, Spanish.

13.

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.

Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.

Neurology. 2012 May 29;78(22):1736-42. doi: 10.1212/WNL.0b013e3182583022. Epub 2012 May 16.

PMID:
22592369
14.

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.

Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M.

J Clin Virol. 2013 Jun;57(2):141-6. doi: 10.1016/j.jcv.2013.02.002. Epub 2013 Mar 5.

PMID:
23465394
15.

Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.

Gupta S, Weinstock-Guttman B.

Expert Opin Biol Ther. 2014 Jan;14(1):115-26. doi: 10.1517/14712598.2014.864634. Epub 2013 Dec 2. Review.

PMID:
24289270
16.

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.

Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C, Hellwig K, Gold R.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1068-74. doi: 10.1136/jnnp-2013-304897. Epub 2013 Apr 19.

17.

[Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?].

Warnke C, Adams O, Gold R, Hartung HP, Hohlfeld R, Wiendl H, Kieseier BC.

Nervenarzt. 2011 Apr;82(4):475-80. doi: 10.1007/s00115-010-3091-8. German.

PMID:
21240604
18.

Natalizumab for relapsing remitting multiple sclerosis.

Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621. doi: 10.1002/14651858.CD007621.pub2. Review.

PMID:
21975773
19.

[Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].

Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.

Duodecim. 2013;129(7):765-70. Finnish.

PMID:
23720945
20.

Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.

Benkert TF, Dietz L, Hartmann EM, Leich E, Rosenwald A, Serfling E, Buttmann M, Berberich-Siebelt F.

PLoS One. 2012;7(12):e52208. doi: 10.1371/journal.pone.0052208. Epub 2012 Dec 20.

Supplemental Content

Support Center